PE20081361A1 - Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas - Google Patents

Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas

Info

Publication number
PE20081361A1
PE20081361A1 PE2007001144A PE2007001144A PE20081361A1 PE 20081361 A1 PE20081361 A1 PE 20081361A1 PE 2007001144 A PE2007001144 A PE 2007001144A PE 2007001144 A PE2007001144 A PE 2007001144A PE 20081361 A1 PE20081361 A1 PE 20081361A1
Authority
PE
Peru
Prior art keywords
solvent
clonazepam
clonazepan
percentage
weight
Prior art date
Application number
PE2007001144A
Other languages
English (en)
Spanish (es)
Inventor
Gene Jamieson
Jardin Michael Des
Clark Allphin
Original Assignee
Jazz Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals filed Critical Jazz Pharmaceuticals
Publication of PE20081361A1 publication Critical patent/PE20081361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2007001144A 2006-08-28 2007-08-23 Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas PE20081361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84056806P 2006-08-28 2006-08-28

Publications (1)

Publication Number Publication Date
PE20081361A1 true PE20081361A1 (es) 2008-11-06

Family

ID=38819711

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001144A PE20081361A1 (es) 2006-08-28 2007-08-23 Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas

Country Status (17)

Country Link
US (2) US8609651B2 (cg-RX-API-DMAC7.html)
EP (2) EP2068933A2 (cg-RX-API-DMAC7.html)
JP (2) JP2010502614A (cg-RX-API-DMAC7.html)
KR (1) KR20090043603A (cg-RX-API-DMAC7.html)
CN (1) CN101528261B (cg-RX-API-DMAC7.html)
AR (1) AR062556A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007290589B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714907A2 (cg-RX-API-DMAC7.html)
CA (1) CA2662197A1 (cg-RX-API-DMAC7.html)
IL (1) IL197275A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009002310A (cg-RX-API-DMAC7.html)
NO (1) NO20091211L (cg-RX-API-DMAC7.html)
NZ (2) NZ575744A (cg-RX-API-DMAC7.html)
PE (1) PE20081361A1 (cg-RX-API-DMAC7.html)
TW (1) TW200824693A (cg-RX-API-DMAC7.html)
UY (1) UY30561A1 (cg-RX-API-DMAC7.html)
WO (2) WO2008027357A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CN106389330A (zh) * 2007-01-19 2017-02-15 哈南亚有限公司 用于递送治疗剂的方法和组合物
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
JP5539875B2 (ja) * 2007-08-31 2014-07-02 アルキメデス・デベロップメント・リミテッド 非水性医薬組成物
GB0716907D0 (en) * 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
US20100273783A1 (en) * 2009-04-28 2010-10-28 Optmed, Inc. Compositions and Methods for Treating and Preventing Overactive Bladder and Conditions Associated Therewith
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
JP2014509655A (ja) * 2011-03-31 2014-04-21 アコルダ セラピュティクス インコーポレーテッド 鼻腔内ベンゾジアゼピン薬剤学的組成物
EP2720699B1 (en) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
KR102190009B1 (ko) 2011-12-11 2020-12-15 바우닥스 바이오, 인코포레이티드 비강내 덱스메데토미딘(dexmedetomidine) 조성물 및 그 사용방법
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
WO2014127459A1 (en) * 2013-02-22 2014-08-28 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines
KR101635635B1 (ko) * 2014-12-04 2016-07-01 주식회사 엘지생활건강 디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물
JP6930922B2 (ja) 2015-05-25 2021-09-01 アイジーエル ファーマ，インコーポレイティド 放射性同位体用ｄｏｔｍｐキット製剤
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
MX393985B (es) * 2016-12-09 2025-03-24 Alexza Pharmaceuticals Inc Metodo para el tratamiento de la epilepsia
CN111886007A (zh) * 2017-11-17 2020-11-03 纽兰娜制药股份有限公司 托哌酮的施用方法
CN111836615A (zh) 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
US10896106B2 (en) * 2018-05-10 2021-01-19 Teradyne, Inc. Bus synchronization system that aggregates status
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US20200338090A1 (en) * 2019-04-29 2020-10-29 Marsh and Wang Medical Systems, LLC Seizure control compositions and methods of using same
CN110420190B (zh) * 2019-08-29 2021-07-09 湖南洞庭药业股份有限公司 氯硝西泮片及其制备方法
CA3221395A1 (en) * 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
CN115707451A (zh) * 2021-08-19 2023-02-21 北京万全德众医药生物技术有限公司 氯硝西泮口服溶液
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN118812444A (zh) * 2022-03-02 2024-10-22 济南同路医药科技发展有限公司 一种喹唑啉类化合物及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266466A (en) * 1987-01-14 1993-11-30 President And Fellows Of Harvard College Method of using T7 DNA polymerase to label the 3' end of a DNA molecule
SE8800080L (sv) 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
FR2656303B1 (fr) 1989-12-26 1994-06-10 Parke Davis Solution buvable d'un derive des benzodiazepines et son application pharmacologique.
ES2117642T3 (es) 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
DE4021263C2 (de) 1990-07-04 1996-04-11 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
FR2692174B1 (fr) 1992-06-16 1994-08-19 Valois Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide.
DK17093D0 (da) 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
AU2345695A (en) * 1994-04-28 1995-11-29 F. Hoffmann-La Roche Ag Pharmaceutical composition for transdermal delivery
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
DE19756442A1 (de) * 1997-12-18 1999-06-24 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9826192D0 (en) * 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
DE60038738T2 (de) * 1999-07-26 2009-07-02 Sk Holdings Co., Ltd. Transnasale anticonvulsive zusammensetzungen
DE19938798A1 (de) * 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) * 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
ATE356636T1 (de) * 2000-08-03 2007-04-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
FR2815611B1 (fr) 2000-10-23 2003-04-11 Valois Sa Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
CA2456754A1 (en) * 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
AU2003215884A1 (en) 2002-02-25 2003-09-09 Lyfjathroun Hf A bioadhesive agent
US6742677B2 (en) 2002-04-18 2004-06-01 Valois S.A.S. Fluid dispenser pump
WO2003099264A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
ITRM20020357A1 (it) 2002-07-03 2004-01-05 Foscama Biomed Chim Farma Composizione liquida per la somministrazione orale di lorazepam.
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
MXPA05008140A (es) 2003-01-31 2005-09-30 Orexo Ab Una composicion farmaceutica de rapida accion.
CN100421649C (zh) 2003-06-17 2008-10-01 Sk株式会社 含地西泮的经鼻微乳
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
JP5107725B2 (ja) * 2005-01-14 2012-12-26 カムルス エービー ＧｎＲＨ類似体製剤
US20070021411A1 (en) 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US9319244B2 (en) 2010-12-22 2016-04-19 Usablenet Inc. Methods for emailing labels as portable data files and devices thereof

Also Published As

Publication number Publication date
JP2010502612A (ja) 2010-01-28
JP2010502614A (ja) 2010-01-28
EP2056877A2 (en) 2009-05-13
BRPI0714907A2 (pt) 2014-08-19
US20080070904A1 (en) 2008-03-20
WO2008027357A2 (en) 2008-03-06
IL197275A0 (en) 2009-12-24
US20080076761A1 (en) 2008-03-27
NZ575744A (en) 2011-10-28
EP2068933A2 (en) 2009-06-17
WO2008027357A9 (en) 2009-04-30
CN101528261A (zh) 2009-09-09
CN101528261B (zh) 2012-07-18
KR20090043603A (ko) 2009-05-06
AU2007290589B2 (en) 2012-04-05
NO20091211L (no) 2009-05-27
WO2008027395A2 (en) 2008-03-06
AR062556A1 (es) 2008-11-19
TW200824693A (en) 2008-06-16
CA2662197A1 (en) 2008-03-06
US8716279B2 (en) 2014-05-06
NZ595388A (en) 2011-12-22
US8609651B2 (en) 2013-12-17
MX2009002310A (es) 2009-09-21
WO2008027395A3 (en) 2008-04-17
UY30561A1 (es) 2008-03-31
AU2007290589A1 (en) 2008-03-06
WO2008027357A3 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
PE20081361A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
BR112015019657A8 (pt) composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato
BRPI0714399B8 (pt) composição farmacêutica líquida oral
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112014029115A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou composição
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BR112014030820A2 (pt) formulação de anticorpos
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
CY1117941T1 (el) Υψηλης συγκεντρωσης φapμαkeytika σκευασματα που περιλαμβανουν το αντισωμα κatα cd20
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
AR064826A1 (es) Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
AR038575A1 (es) Formulacion oftalmica con nueva composicion de goma
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
CO6400138A2 (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
ES2720954T3 (es) Formulaciones estabilizadas de estatina
PE20210413A1 (es) Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids

Legal Events

Date Code Title Description
FC Refusal